The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•4 May 2026•

1 min read

FDA Approves Lannett's LANGLARA as Interchangeable Biosimilar for Lantus

Key Facts

1The U.S. FDA approved LANGLARA as an interchangeable biosimilar to Lantus for the treatment of type 1 and type 2 diabetes.

Lannett Company and its partners have received U.S. FDA approval for LANGLARA, marking a significant milestone as an interchangeable biosimilar to the blockbuster insulin drug Lantus. The approval covers the treatment of both type 1 and type 2 diabetes, offering a new cost-effective option for patients. By achieving the 'interchangeable' designation, LANGLARA can be substituted for Lantus at the pharmacy level without requiring a change to the prescription. This development is the result of a strategic collaboration between Lannett, Lanexa Biologics, and Sunshine Lake Pharma. Regulatory approval of such a biosimilar is viewed as a major catalyst for Lannett's market positioning within the pharmaceutical sector. Industry analysts expect this move to increase competition in the insulin market and potentially lower healthcare costs. The company is now poised to leverage this approval to capture a share of the high-demand diabetes care market.